Current
Neuro-Oncology


Volume 21 Number 4
April 2019


Home > Disciplines > Publications > Current Neuro-Oncology > Volume 21, Year 2019 > Number 4, April


CONTENTS


CENTRAL NERVOUS SYSTEM TUMORS

GLIOMAS
BRAIN STEM GLIOMAS
DIFFUSE MIDLINE GLIOMAS
HIGH-GRADE GLIOMAS
LOW-GRADE GLIOMAS

DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS
GLIOBLASTOMA
OLIGODENDROGLIOMAS
OLIGODENDROGLIOMA

EMBRYONAL TUMORS
MEDULLOBLASTOMA





CENTRAL NERVOUS SYSTEM TUMORS

.

Nilsson J, Järås J, Henriksson R, Holgersson G, Bergström S, Estenberg J, Augustsson T, Bergqvist M.
No Evidence for Increased Brain Tumour Incidence in the Swedish National Cancer Register Between Years 1980-2012.
Anticancer Res. 2019 Feb;39(2):791-796. doi: 10.21873/anticanres.13176.
Source | Full text | Similar articles



GLIOMAS



DIFFUSE MIDLINE GLIOMAS


.

Perez A, Merlini L, El-Ayadi M, Korff C, Ansari M, von Bueren AO.
Comment on: Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study.
Pediatr Blood Cancer. 2019 Feb 15:e27664. doi: 10.1002/pbc.27664. [Epub ahead of print]
Source | Full text | Similar articles
Article review referring to: van der Louw EJTM, et al., Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study.
Pediatr Blood Cancer. 2018 Nov 28:e27561. doi: 10.1002/pbc.27561. [Epub ahead of print].
Source | Full text



HIGH-GRADE GLIOMAS


.

Kikuchi R, Ueda R, Saito K, Shibao S, Nagashima H, Tamura R, Morimoto Y, Sasaki H, Noji S, Kawakami Y, Yoshida K, Toda M.
A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma.
J Clin Med. 2019 Feb 20;8(2). pii: E263. doi: 10.3390/jcm8020263.
Source | Full text | Similar articles



.

Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY.
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Neuro Oncol. 2019 Feb 12. doi: 10.1093/neuonc/noz040. [Epub ahead of print]
Source | Full text | Similar articles



LOW-GRADE GLIOMAS


.

Kamran SC, Dworkin M, Niemierko A, Bussiere M, Oh KS, Loeffler JS, Shih HA.
Patterns of failure among low-grade glioma patients treated with proton radiotherapy.
Pract Radiat Oncol. 2019 Feb 18. pii: S1879-8500(19)30049-9. doi: 10.1016/j.prro.2019.02.002. [Epub ahead of print]
Source | Full text | Similar articles



.

Ludmir EB, Mahajan A, Paulino AC, Jones JY, Ketonen LM, Su JM, Grosshans DR, McAleer MF, McGovern SL, Lassen-Ramshad YA, Adesina AM, Dauser RC, Weinberg JS, Chintagumpala MM.
Increased Risk of Pseudoprogression among Pediatric Low-Grade Glioma Patients Treated with Proton versus Photon Radiotherapy.
Neuro Oncol. 2019 Feb 7. doi: 10.1093/neuonc/noz042. [Epub ahead of print]
Source | Full text | Similar articles



DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS



GLIOBLASTOMA


.

Akgül S, Patch AM, D'Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoff SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N, Day BW.
Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma.
Cancers (Basel). 2019 Feb 6;11(2). pii: E190. doi: 10.3390/cancers11020190.
Source | Full text | Similar articles



.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
Source | Full text | Similar articles



.

Cobbs C, McClay E, Duic JP, Nabors LB, Morgan Murray D, Kesari S.
An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US.
CNS Oncol. 2019 Mar;8(1):CNS30. doi: 10.2217/cns-2018-0013. Epub 2018 Dec 14.
Source | Full text | Similar articles



.

De Barros A, Attal J, Roques M, Nicolau J, Sol JC, Cohen-Jonathan-Moyal E, Roux FE.
Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma.
J Neurooncol. 2019 Feb 19. doi: 10.1007/s11060-019-03120-3. [Epub ahead of print]
Source | Full text | Similar articles



.

Esquenazi Y, Moss N, Tabar V.
In Reply: Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2019 Mar 5. pii: nyz010. doi: 10.1093/neuros/nyz010. [Epub ahead of print]
Source | Full text | Similar articles
Correspondence referring to:
Wang T et al., Letter: Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2019 Feb 16. pii: nyz009. doi: 10.1093/neuros/nyz009. [Epub ahead of print].
Source | Full text
In turn referring to:
Esquenazi Y, et al., Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2018 Jul 1;83(1):76-85. doi: 10.1093/neuros/nyx349.
Source | Full text



.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4.
Source | Full text | Similar articles



.

Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S, Campian JL.
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
J Neurooncol. 2019 Feb 15. doi: 10.1007/s11060-019-03125-y. [Epub ahead of print]
Source | Full text | Similar articles



.

Ito H, Nakashima H, Chiocca EA.
Molecular responses to immune checkpoint blockade in glioblastoma.
Nat Med. 2019 Mar;25(3):359-361. doi: 10.1038/s41591-019-0385-7.
Source | Full text | Similar articles
Article review referring to:
Zhao J, et al., Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11.
Source | Full text
Schalper KA, et al., Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.
Source | Full text
Cloughesy TF, et al., Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11. Source | Full text



.

Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, Bhattacharjee MB, Zhu JJ.
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.
Front Neurol. 2019 Jan 31;10:42. doi: 10.3389/fneur.2019.00042. eCollection 2019.
Source | Full text | Similar articles



.

Murphy M, Dowling A, Thien C, Priest E, Morgan Murray D, Kesari S.
A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia.
CNS Oncol. 2019 Mar;8(1):CNS31. doi: 10.2217/cns-2018-0017. Epub 2019 Feb 7.
Source | Full text | Similar articles



.

Pozzoli G, Marei HE, Althani A, Boninsegna A, Casalbore P, Marlier LNJL, Lanzilli G, Zonfrillo M, Petrucci G, Rocca B, Navarra P, Sgambato A, Cenciarelli C.
Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation.
J Cell Physiol. 2019 Jan 30. doi: 10.1002/jcp.28194. [Epub ahead of print]
Source | Full text | Similar articles



.

Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A, Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO, Suwan K, Hajitou A.
Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.
EMBO Mol Med. 2019 Feb 26. pii: e8492. doi: 10.15252/emmm.201708492. [Epub ahead of print]
Source | Full text | Similar articles



.

Rodríguez-Lozano DC, Piña-Medina AG, Hansberg-Pastor V, Bello-Alvarez C, Camacho-Arroyo I.
Testosterone Promotes Glioblastoma Cell Proliferation, Migration, and Invasion Through Androgen Receptor Activation.
Front Endocrinol (Lausanne). 2019 Feb 4;10:16. doi: 10.3389/fendo.2019.00016. eCollection 2019.
Source | Full text | Similar articles



.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.
Source | Full text | Similar articles



.

Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology.
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
J Neurooncol. 2019 Feb 6. doi: 10.1007/s11060-019-03116-z. [Epub ahead of print]
Source | Full text | Similar articles



.

Stupp R, Lukas RV, Hegi ME.
Improving survival in molecularly selected glioblastoma.
Lancet. 2019 Feb 16;393(10172):615-617. doi: 10.1016/S0140-6736(18)33211-2.
Source | Full text | Similar articles
Comment on: Herrlinger U, et al., Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4.
Source | Full text



.

Wang T, Long Q, Gao T.
Letter: Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2019 Feb 16. pii: nyz009. doi: 10.1093/neuros/nyz009. [Epub ahead of print]
Source | Full text | Similar articles
Comment on:
Esquenazi Y, et al., Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2018 Jul 1;83(1):76-85. doi: 10.1093/neuros/nyx349.
Source | Full text



.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.
Source | Full text | Similar articles



.

Woo PYM, Ho JMK, Tse TPK, Lam SW, Mak CHK, Chan DTM, Lee MWY, Wong ST, Chan KY, Poon WS.
Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
J Clin Neurosci. 2019 Jan 31. pii: S0967-5868(18)31734-X. doi: 10.1016/j.jocn.2019.01.022. [Epub ahead of print]
Source | Full text | Similar articles



.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11.
Source | Full text | Similar articles



OLIGODENDROGLIOMAS




OLIGODENDROGLIOMA


.

Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA.
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Oncologist. 2019 Feb 18. pii: theoncologist.2018-0549. doi: 10.1634/theoncologist.2018-0549. [Epub ahead of print]
Source | Abstract | Similar articles



EMBRYONAL TUMORS



MEDULLOBLASTOMA


.

Perez-Somarriba M, Andión M, López-Pino MA, Lavarino C, Madero L, Lassaletta A.
Old drugs still work! Oral etoposide in a relapsed medulloblastoma.
Childs Nerv Syst. 2019 Feb 1. doi: 10.1007/s00381-019-04072-9. [Epub ahead of print]
Source | Full text | Similar articles



.

Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King A, Howell R, Gibson TM, Krull KR, Robison LL, Oeffinger KC, Fouladi M, Armstrong GT.
Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study.
J Clin Oncol. 2019 Mar 20;37(9):731-740. doi: 10.1200/JCO.18.00969. Epub 2019 Feb 7.
Source | Full text | Similar articles



bottom